Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
出版年份 2020 全文链接
标题
Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial
作者
关键词
-
出版物
LANCET ONCOLOGY
Volume 22, Issue 1, Pages 29-42
出版商
Elsevier BV
发表日期
2020-12-08
DOI
10.1016/s1470-2045(20)30555-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Outcome measures in multimodal rectal cancer trials
- (2020) Emmanouil Fokas et al. LANCET ONCOLOGY
- Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial
- (2020) Maxime J.M. van der Valk et al. RADIOTHERAPY AND ONCOLOGY
- International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic
- (2020) C.A.M. Marijnen et al. RADIOTHERAPY AND ONCOLOGY
- Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12
- (2019) Emmanouil Fokas et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour regression after radiotherapy for rectal cancer – Results from the randomised Stockholm III trial
- (2019) Johan Erlandsson et al. RADIOTHERAPY AND ONCOLOGY
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study
- (2018) Maxime J M van der Valk et al. LANCET
- 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial
- (2018) Timothy J Iveson et al. LANCET ONCOLOGY
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer
- (2018) Michael R. Marco et al. DISEASES OF THE COLON & RECTUM
- Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting
- (2017) Regina G. H. Beets-Tan et al. EUROPEAN RADIOLOGY
- Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
- (2017) Johan Erlandsson et al. LANCET ONCOLOGY
- Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study
- (2016) K. Bujko et al. ANNALS OF ONCOLOGY
- Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin
- (2015) K. Bujko et al. EJSO
- Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial
- (2015) Julio Garcia-Aguilar et al. LANCET ONCOLOGY
- Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
- (2015) Anne J Breugom et al. LANCET ONCOLOGY
- Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial
- (2014) A. J. Breugom et al. ANNALS OF ONCOLOGY
- Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer†
- (2013) T. H. van Dijk et al. ANNALS OF ONCOLOGY
- Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer – the RAPIDO trial
- (2013) Per J Nilsson et al. BMC CANCER
- Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients With T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04
- (2012) Samuel Y. Ngan et al. JOURNAL OF CLINICAL ONCOLOGY
- Anterior resection syndrome
- (2012) Catherine LC Bryant et al. LANCET ONCOLOGY
- Competing risks and the clinical community: irrelevance or ignorance?
- (2011) Michael T. Koller et al. STATISTICS IN MEDICINE
- Evaluation of Biologic Effective Dose and Schedule of Fractionation for Preoperative Radiotherapy for Rectal Cancer: Meta-Analyses and Meta-Regression
- (2010) Gustavo Arruda Viani et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data
- (2010) Monique Maas et al. LANCET ONCOLOGY
- A uniform residual tumor (R) classification
- (2009) Christian Wittekind et al. CANCER
- Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)
- (2009) Vincenzo Valentini et al. RADIOTHERAPY AND ONCOLOGY
- Randomized Phase III Study Comparing Preoperative Radiotherapy With Chemoradiotherapy in Nonresectable Rectal Cancer
- (2008) Morten Brændengen et al. JOURNAL OF CLINICAL ONCOLOGY
- Short-course preoperative radiotherapy with delayed surgery in rectal cancer – A retrospective study
- (2008) Calin Radu et al. RADIOTHERAPY AND ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started